Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has been given a consensus recommendation of “Hold” by the twenty-three research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $42.93.
A number of brokerages have issued reports on PCRX. Mizuho downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $53.00 to $44.00 in a report on Wednesday, November 29th. HC Wainwright set a $55.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Canaccord Genuity set a $46.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Royal Bank of Canada set a $54.00 price target on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.60% of the company’s stock.
Large investors have recently modified their holdings of the business. Rice Hall James & Associates LLC grew its stake in shares of Pacira Pharmaceuticals by 18.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 323,769 shares of the company’s stock worth $14,780,000 after buying an additional 50,335 shares in the last quarter. Mesirow Financial Investment Management Equity Management grew its stake in shares of Pacira Pharmaceuticals by 5.1% in the 4th quarter. Mesirow Financial Investment Management Equity Management now owns 410,561 shares of the company’s stock worth $18,742,000 after buying an additional 19,876 shares in the last quarter. Legacy Capital Partners Inc. grew its stake in shares of Pacira Pharmaceuticals by 6.5% in the 4th quarter. Legacy Capital Partners Inc. now owns 50,493 shares of the company’s stock worth $2,305,000 after buying an additional 3,100 shares in the last quarter. Epoch Investment Partners Inc. grew its stake in shares of Pacira Pharmaceuticals by 195.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after buying an additional 354,728 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Pacira Pharmaceuticals by 8.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 236,058 shares of the company’s stock worth $8,865,000 after buying an additional 17,971 shares in the last quarter.
Shares of Pacira Pharmaceuticals (PCRX) traded down $0.40 during mid-day trading on Friday, hitting $30.15. 831,976 shares of the stock traded hands, compared to its average volume of 1,021,022. The company has a market cap of $1,296.67, a P/E ratio of -27.66 and a beta of 1.95. Pacira Pharmaceuticals has a 12-month low of $29.35 and a 12-month high of $52.47. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.46. The firm had revenue of $79.08 million for the quarter, compared to the consensus estimate of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The company’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm earned $0.09 EPS. equities analysts expect that Pacira Pharmaceuticals will post -0.64 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/15/pacira-pharmaceuticals-inc-pcrx-given-average-recommendation-of-hold-by-brokerages.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.